Glucocorticoids and immunoglobulins, the first‐line treatments of ITP, and other therapeutic agents, such as thrombopoietin receptor agonists, spleen tyrosine kinase (Syk) inhibitors, and Bruton tyrosine kinase inhibitor (BTKi),[13, 14] can play therapeutic roles by regulating Fcγ receptor‐mediated macrophage phagocytosis. This evidence concerns the gene SYK and autoimmune thrombocytopenic purpura.